FierceBiotechOriginal article
{"a":[{"_":"Werewolf transforms into Ambros via reverse merger to support phase 3 push for rare disease drug ","$":{"href":"/biotech/werewolf-transforming-reverse-merger-support-ambros-phase-3-push","hreflang":"en"}}]}
Positive
AI Analysis
Summary
Ambros Therapeutics has agreed to merge with Werewolf Therapeutics in an all-stock deal and raised $150 million to advance its lead rare disease drug candidate through Phase 3 toward regulatory filing.
Clinical Trial Data
Phase
3
Outcome Details
All-stock merger with $150 million capital raise
Importance:7/10
Sentiment:
0.60
mergerrare diseasephase 3capital raisestrategic alternative
Read the original article
Published by FierceBiotech on August 21, 2026 9:15 AM